Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal fractional-dose mRNA-1273 vaccination in fibrodysplasia ossificans progressiva
2022-000692-39Phase 2Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Amsterdam University Medical Center. Primary endpoint: Local reactogenicity and tolerability. Started Mar 2023; status: active.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000692-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000692-39.